

Editorial Note

©2012 NRITLD, National Research Institute of Tuberculosis and Lung Disease, Iran

ISSN: 1735-0344 Tanaffos 2012; 11 (1): 6

TANAFFOS 

ATS and our Journal Collaboration

After active participation of ATS with the attendance of Prof. Nicholas Hill, president of the ATS, in the 5th NRITLD international congress of tuberculosis and pulmonary diseases held 15-18 October 2011 in Iran and following the agreement between NRITLD and ATS for future scientific and research cooperation, Tanaffos Journal is proud to announce that some scholar ATS members accepted our invitation to join the editorial board of the journal.

Dr. Esmaeil Mortaz
Assistant to Editor-in-Chief

ATS NEWS AMERICAN THORACIC SOCIETY • <http://news.thoracic.org>

ATS MEMBERS JOIN EDITORIAL TEAM OF IRANIAN JOURNAL

ATS members Peter Barnes and Irfan Rahman have joined the editorial board of *Tanaffos*, a peer-reviewed journal published by the National Research Institute of Tuberculosis and Lung Disease (NRITLD) at the Shahid Beheshti University of Medical Sciences and Health Services in Tehran, Iran. *Tanaffos*, which means "respiration" in Farsi, Arabic, Kurdish, Urdu and Turkish, publishes original papers, selected review articles, case reports and other articles of special interest related to respiratory disease. All papers are published in English. The journal's editor is Mohammad Reza Masjedi, MD.

In October 2011, ATS President Nick Hill attended the 5th Semi-Annual International Congress on Pulmonary Diseases, Intensive Care and Tuberculosis in Tehran, Iran (see story), where he signed a memorandum of understanding between the ATS and the NRITLD aimed at increasing scientific collaboration between the two organizations.

Original research topics covered in *Tanaffos*, which publishes papers from around the world, have included lung cell biology, immunology, pathology, epidemiology, pathophysiology, thoracic imaging, pediatric pulmonology, sleep medicine, oncology, occupational medicine, intensive care, thoracic surgery, and tuberculosis. The journal, which is published quarterly, will produce a special supplement in December 2012 focusing on respiratory health in the developing world.

"The *Tanaffos* journal takes its role as an advocate for better respiratory publications nationally and internationally very seriously," said Esmaeil Mortaz, PhD, assistant to the editor-in-chief of the journal. "In Iran and many developing countries, TB is still a serious and important health issue and the exact data on prevalence of asthma and COPD, lung cancer and many other major respiratory problems are lacking." ■

of fantastically bright and engaged colleagues, which is the joy of a career in academic medicine."

"Overall, I am mindful that the directions of my research career relate to some serendipitous twists coupled with an interest in many disciplines, including clinical epidemiology, pulmonary and critical care medicine, and organizational development, and that I am the product of the admixture of these themes," he added. "Frankly, I could not have predicted this at the outset of my career and am delighted for the surprise." ■



- In January 2012, Actelion Pharma Inc. and XenoPort, Inc. received marketing approval in Japan for Regnite® (gabapentin enacarbil) for the treatment of moderate-to-severe primary restless legs syndrome (RLS). Regnite® has a different mechanism of action than other RLS treatments currently available in Japan. Regnite® is dosed once daily. It has been shown in clinical studies to improve International Restless Legs Syndrome Rating Scale scores compared to placebo.
- On January 23, 2012, Alere Inc. announced FDA approval of its Influenza A&B Test for use in the United States. The Alere™ Influenza A&B Test is intended for use in the physician's office. It uses highly sensitive antibodies to detect influenza types A and B antigen. Sample collection for the test is performed with a nasal swab. Results are provided in 10 minutes, making it possible for physicians to administer treatment while patients are still in the office.
- Also in January, the FDA granted 510k clearance to Riverain Technologies' Temporal Comparison software, which is designed to electronically compare current and prior chest X-ray images and help identify nodules that may be early-stage lung cancer. The software aligns and registers the two images to produce a third, subtraction image, which allows radiologists to pinpoint subtle changes that show up more clearly than on a traditional X-ray. Temporal Comparison also has received approval for marketing in the European Union.

The image above does not represent the products described in this column.